ACUTE LYMPHOCYTIC LEUKAEMIA FOR INDUCTION OF REMISSION. NOT FOR MAINTENANCE THERAPY: As a part of multidrug iduction regimens: IV: 1000 IU/kg/day for 10 successive days as part of regimen with Prednisone, Vincristine sulphate or IM: 6000 IU/m2 on Days 4,7,10,13,16,19,22,25,28 of the treatment period with prednisone and vincristine sulpahte.
SOLE AGENT FOR INDUCTION OF REMISSION: Adults and children: 200 IU/KG intravenously daily for 28 days. NOTE: When administered IV, drug should be given over 30 mins along with normal saline/5% dextrose.
Rapidly depletes asparagine from malignant cells which depend on exogenous sources for survival. Normal cells can synthesize asparagine and are affected less. L-Asparaginase induces remission in some patients with acute lymphocytic leukaemie.
Vincristine and Prednisone: Associated with increased toxicity.
Methotrexate: Effect on malignant cells diminished or abolished as long as plasma asparginase levels are suppressed.
Cytarabine: Synegistic effect.
Lab Tests: Thyroid function tests: Interferes with its interpretation.
Effect & Precautions
Nausea, vomiting, headache, fever, abdominal pain, hyperglycaemia leading to coma, hypersensitivity, renal damge, coagulation defects, trombosis, CNS depression or hyperexcitability, acute haemorrhageic pancreatits.
Pregnancy: Use only if potential benefit justifies risk to the foetus
Breast Feeding: Discontinue nursing or the drug.
Man: Use with caution.